

1 **Surveillance of seasonal respiratory viruses among Chilean patients during the**  
2 **COVID-19 pandemic.**

3  
4 Luis A. Alonso-Palomares<sup>1,3,5\*</sup>, C. Joaquín Cáceres<sup>6</sup>, Rodrigo Tapia<sup>2</sup>, Paulina Aguilera-  
5 Cortés<sup>3,5</sup>, Santiago Valenzuela<sup>4</sup>, Fernando Valiente-Echeverría<sup>1,3,5</sup>, Ricardo Soto-Rifo<sup>1,3,5</sup>,  
6 Aldo Gaggero<sup>1,4</sup>, and Gonzalo P. Barriga<sup>1,2#</sup>.

7  
8 <sup>1</sup> SARS-CoV-2 Research Group, Virology Program, Institute of Biomedical Sciences,  
9 Faculty of Medicine, Universidad de Chile.

10 <sup>2</sup> Laboratory of Emerging Viruses, Virology Program, Institute of Biomedical Sciences,  
11 Faculty of Medicine, Universidad de Chile

12 <sup>3</sup> Laboratory of Molecular and Cellular Virology, Virology Program, Institute of  
13 Biomedical Sciences, Faculty of Medicine, Universidad de Chile

14 <sup>4</sup> Laboratory of Environmental Virology, Virology Program, Institute of Biomedical  
15 Sciences, Faculty of Medicine, Universidad de Chile

16 <sup>5</sup> HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile

17 <sup>6</sup> Department of Population Health, College of Veterinary Medicine, University of  
18 Georgia, Athens, Georgia, USA

19  
20  
21 # To whom correspondence should be addressed: Dr. Gonzalo Barriga,  
22 (gonzalo.barriga@uchile.cl), Emerging Viruses Laboratory, Virology Program, Institute of  
23 Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Independencia 1027,  
24 Santiago, Chile

25  
26  
27  
28 Keywords: Surveillance, respiratory viruses, SARS-CoV-2, Influenza virus, RSV, Rhinovirus

29  
30  
31

## 32 **The Study**

33 SARS-CoV-2 has generated over 122 million cases worldwide. Non-pharmaceuticals  
34 interventions such as confinements and lockdowns started in Chile on March 18<sup>th</sup> 2020.

35 In Europe, confinements and lockdowns have been accompanied by a decrease in the  
36 circulation of other respiratory viruses such as Influenza A virus(IAV), Influenza B  
37 virus(IBV) or respiratory syncytial virus(RSV) (1). Although changes in circulation  
38 patterns of respiratory viruses have been reported, limited information regarding the  
39 southern hemisphere is available where the SARS-CoV-2 pandemic merged with the  
40 winter season. We conducted viral surveillance of respiratory viruses and we evaluated  
41 their presence and establishing whether they were co-circulating with SARS-CoV-2.

42 Few south hemisphere countries reported the same pattern than Europe where non-  
43 pharmaceutical measures began before the winter season (2, 3) but to the best to our  
44 knowledge, no report has been generated containing information from Chile. Here, we  
45 collected 800 nasopharyngeal-swabs samples (NSS) from 13 health care centers  
46 belonging to the north area of Santiago, Chile, between April 1<sup>st</sup> to July 31<sup>st</sup>, 2020 (Figure  
47 1). All samples were collected from patients with at least one COVID-19 symptoms. 400  
48 samples were determined as positive for SARS-CoV-2. 64% percent of SARS-CoV-2  
49 positive individuals showed age range between 23-57 years. In addition, women had a  
50 significant incidence of positive cases, corresponding to 59% in age range group (Figure  
51 2).

52 Next, based on geographic location we divided the samples in 3 groups (A, B and C)  
53 Figure 1. Location (A) contains the highest number of SARS-CoV-2 cases, contributing  
54 more than 50% of the positive samples analyzed in this study (Figure 1). This high  
55 positivity could be explained by the population density of location A, which contains at

56 least 4-fold more inhabitants than locations B and C (Figure 1). Nevertheless, the health  
57 centers located in B presented positivity rates higher than 61% for SARS-CoV2 (Table 1),  
58 except for sub-locations 9 and 10 (Figure 1), where no positive samples were obtained  
59 in the period analyzed. Location C is farthest location from downtown, however, still has  
60 a positivity of 54.8% indicating a homogeneous distribution of SARS-CoV-2.

61 Taken together, our data show a high frequency of positive samples throughout the  
62 healthcare centers evaluated suggesting the population density as a risk factor for SARS-  
63 CoV-2 transmission since location A and B concentrates more population than location  
64 C. These results demonstrate that the 2020 winter season in Santiago presented a high  
65 incidence of SARS-CoV-2.

66 Then, we sought to determine in all samples whether SARS-CoV-2 was co-circulating  
67 with other respiratory viruses. We chose predominant respiratory viruses in Santiago  
68 (winter season), such as: IAV, IBV, RSV and human rhinovirus (HRV) (Table 1).  
69 Adenovirus, Parainfluenza and Metapneumovirus were not evaluated since they are  
70 considered all-year viruses (4). The results showed three samples with co-infection  
71 between IAV and SARS-CoV-2 (Table 1). This is congruent to recent studies in Ecuador  
72 and Brazil showing complete decrease of IAV (5, 6). Despite the co-circulation or co-  
73 infection between IAV and SARS-CoV-2 observed, we could not detect RSV or IBV in the  
74 SARS-CoV-2 positive samples. These results suggest an impact of the non-  
75 pharmaceutical interventions in the circulation of seasonal viruses, as previously  
76 reported in Korea and Hong Kong (7, 8). Next, we evaluated the presence of IAV, IBV and  
77 RSV in the samples reported as negative for SARS-CoV-2 where five positive samples for  
78 IAV and no positive samples for IBV or RSV were detected, suggesting a circulation of  
79 these viruses below 1% considering the amount of samples evaluated (Table 1). This is

80 lower than the information from the northern hemisphere where a range between 2-  
81 10% has been reported (9, 10). Taken together, these results suggest a lower co-  
82 circulation of IAV with SARS-CoV-2 and co-circulation below the level of detection of this  
83 study for SARS-CoV-2 together with IBV or RSV.

84 Finally, we focused on HRV, responsible for more than 50% of the cold-like illnesses, with  
85 a high preponderance to coinfection with other respiratory viral pathogens(11).  
86 Furthermore, HRV was the predominant virus after SARS-CoV-2 detected either  
87 cocirculating with SARS-CoV-2 or circulating alone(9). The presence of HRV was  
88 assessed, showing that 0.25% of the samples were co-infected SARS-CoV-2/HRV. On the  
89 other hand, the HRV co-circulation was 0.8% (Table 1). These results establish HRV co-  
90 circulation and the co-infection with SARS-CoV-2. Taken together, these results  
91 demonstrate the displacement of seasonal respiratory viruses due to the presence of  
92 SARS-CoV-2. Despite of this displacement, IAV and HRV are still able to keep  
93 cocirculating together with SARS-CoV-2 but to a considerably lesser extent in  
94 comparison with previous winter seasons.

95

## 96 **Discussion**

97 To gain insights into the potential co-circulation of the most relevant seasonally  
98 circulating respiratory viruses together with SARS-CoV-2, a fact on going COVID-19  
99 pandemic was that the vast majority of the SARS-CoV-2 testing during the April-July  
100 period was indicated only with the presence of symptoms, we arbitrarily selected 200  
101 samples per month (April to July) for a total of 800 NSS from 13 health care centers  
102 located in the north zone of Santiago, Chile.

103 We detected a high positivity rate by health care center between 30,4%-72% and we  
104 observed at least twice co-infections between SARS-CoV-2/IAV or SARS-CoV-2/HRV and  
105 no co-infections with IBV and RSV, which is in agreement with previously reported data  
106 including the southern hemisphere (5,12). Furthermore, IAV and HRV were detected  
107 from negative SARS-CoV-2 samples, whereas no presence of IBV or RSV was obtained  
108 even from the negative SARS-CoV-2 samples (Table 1). These results demonstrate the  
109 displacement of the predominant seasonal respiratory viruses, which have an essential  
110 impact during the winter season caused by the high circulation rate of SARS-CoV-2. A  
111 similar phenomenon was observed after the 2009 Influenza A (H1N1) pandemic, which  
112 generated a decrease of RSV and IAV H3N2 infections (13). The reduction or absence of  
113 IAV, IBV or RSV observed in this study can be explained by the non-pharmaceutical  
114 interventions such as confinement and lockdowns established before the beginning of  
115 the winter season in March 2020. A previous report showed that SARS-CoV-2 could  
116 replace within three weeks the seasonal respiratory viruses circulating (1), while that  
117 HRV co-infections are one of the most commonly observed. However, the impact that  
118 HRV infection co-infecting with other respiratory viruses is still unclear due to  
119 inconsistencies among different studies (11). The effect of HRV in SARS-CoV-2 infection  
120 and the clinical outcome is still unknown.

121 Considering that the vast majority of the SARS-CoV-2 testing during the April-July period  
122 was indicated only with the presence of symptoms, potential bacterial infections or co-  
123 infections cannot be ruled out in this study. The presence of bacterial infections during  
124 the SARS-CoV-2 pandemic has been previously reported (14-16). A previous study  
125 identified *S. Pneumoniae*, *K. pneumoniae* and *H. influenza* among the bacteria

126 cocirculating with SARS-CoV-2 (16). However, the detection of bacteria is beyond the  
127 scope of the study

128 In conclusion, the data shows the impact of SARS-CoV-2 over the co-circulation of  
129 seasonal respiratory viruses like IAV, IBV, and RSV in Chile. Our results suggest that the  
130 emergence of SARS-CoV-2 in addition with different non-pharmaceutical measures  
131 adopted worldwide have a detrimental impact on the circulation at least of seasonal  
132 respiratory viruses. Furthermore, our data allow us to foresee the circulation of  
133 respiratory viruses in the 2021 winter season in the southern hemisphere.

134

135 **Conflict of interest**

136 The authors declare that there are no conflicts of interest associated with this work  
137

138 **Ethical statement**

139 The study described here was approved by the Ethics Committee of the Faculty of  
140 Medicine at Universidad de Chile (Project N° 036-2020). The samples were de-identified  
141 and not considered as human samples.

142

143 **Acknowledgments and Funding**

144 The authors are supported by Instituto Antártico Chileno (INACH) RT\_35-19 (GB-P), ANID  
145 Chile through Fondecyt grants N° 11200228 (GB) 1181656 (AG), 1190156 (RS-R),  
146 1180798 (FV-E); Postdoctoral fellowship N° SECTEI/138/2019 from Mexico City (LA-P).  
147 Authors would like to thank the Science, Technology, Knowledge and Innovation  
148 Ministry of Chile for articulating and coordinating support from the scientific  
149 community. Also, we want to thank the diagnostic group of the University of Chile

150

151 **Authors contributions.**

152 Conceptualization: LAP, CJC and GB, Data curation: LAP, RT, PA, AG, FV-E and GB, Formal  
153 analysis: LAP and GB, Funding acquisition: GB, Investigation: LAP, RT, PA, SV and GB,  
154 Methodology: LAP, CJC, FAV-E, AG, RS-R and GB, Project administration: LAP, CJC, FV-E,  
155 AG, RS-R and GB.

156 Supervision: LAP, FAV-E, AG, RS-R and GB, Validation: LAP, CJC, and GB, Visualization:  
157 LAP, CJC, and GB, Writing-original & draft: CJC, and GB, Writing-review & editing: LAP,  
158 CJC, FAV-E, AG, RS-R and GB, All authors approved the final version of the manuscript.  
159 Gonzalo Barriga had full data access to all data in this study and takes complete  
160 responsibility for the integrity of the data and the accuracy of the data analysis.

161

162 **Transparency statement**

163 Gonzalo Barriga affirms that this manuscript is an honest, accurate, and transparent  
164 account of the study being reported; that no important aspects of the study have been  
165 omitted; and that any discrepancies from the study as planned have been explained

166

167 **Data availability statement**

168 The authors confirm that the data supporting the findings of this study and its  
169 supplementary materials.

170




171 **References**

172

- 173 1. Leuzinger K, Roloff T, Gosert R, Sogaard K, Naegele K, Rentsch K, et al.  
174 Epidemiology of SARS-CoV-2 Emergence Amidst Community-Acquired Respiratory  
175 Viruses. *J Infect Dis.* 2020 Jul 29.
- 176 2. Ortiz-Prado E, Simbana-Rivera K, Barreno LG, Diaz AM, Barreto A, Moyano C, et  
177 al. Epidemiological, socio-demographic and clinical features of the early phase of the  
178 COVID-19 epidemic in Ecuador. *PLoS Negl Trop Dis.* 2021 Jan;15(1):e0008958.
- 179 3. Goes LGB, Zerbinati RM, Tateno AF, de Souza AV, Ebach F, Corman VM, et al.  
180 Typical epidemiology of respiratory virus infections in a Brazilian slum. *J Med Virol.* 2020  
181 Aug;92(8):1316-21.
- 182 4. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral  
183 Infections. *Annu Rev Virol.* 2020 Mar 20.
- 184 5. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, et al. The epidemiology and clinical  
185 characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during  
186 COVID-19 outbreak. *J Med Virol.* 2020 Jun 12.
- 187 6. Konala VM, Adapa S, Naramala S, Chenna A, Lamichhane S, Garlapati PR, et al. A  
188 Case Series of Patients Coinfected With Influenza and COVID-19. *J Investig Med High*  
189 *Impact Case Rep.* 2020 Jan-Dec;8:2324709620934674.
- 190 7. Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact assessment  
191 of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in  
192 Hong Kong: an observational study. *Lancet Public Health.* 2020 May;5(5):e279-e88.
- 193 8. Choe YJ, Lee JK. The Impact of Social Distancing on the Transmission of Influenza  
194 Virus, South Korea, 2020. *Osong Public Health Res Perspect.* 2020 Jun;11(3):91-2.
- 195 9. Nowak MD, Sordillo EM, Gitman MR, Paniz Mondolfi AE. Co-infection in SARS-  
196 CoV-2 infected Patients: Where Are Influenza Virus and Rhinovirus/Enterovirus? *J Med*  
197 *Virol.* 2020 Apr 30.
- 198 10. Mutnal MB, Arroliga AC, Walker K, Mohammad A, Brigmon MM, Beaver RM, et  
199 al. Early trends for SARS-CoV-2 infection in central and north Texas and impact on other  
200 circulating respiratory viruses. *J Med Virol.* 2020 May 15.
- 201 11. Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. *Clin*  
202 *Microbiol Rev.* 2013 Jan;26(1):135-62.
- 203 12. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. Co-infection with SARS-CoV-2  
204 and Influenza A Virus in Patient with Pneumonia, China. *Emerg Infect Dis.* 2020  
205 Jun;26(6):1324-6.
- 206 13. Yang L, Chan KH, Suen LK, Chan KP, Wang X, Cao P, et al. Impact of the 2009 H1N1  
207 Pandemic on Age-Specific Epidemic Curves of Other Respiratory Viruses: A Comparison  
208 of Pre-Pandemic, Pandemic and Post-Pandemic Periods in a Subtropical City. *PLoS One.*  
209 2015;10(4):e0125447.
- 210 14. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al.  
211 Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid  
212 review and meta-analysis. *Clin Microbiol Infect.* 2020 Jul 22.
- 213 15. Lehmann CJ, Pho MT, Pitrak D, Ridgway JP, Pettit NN. Community Acquired Co-  
214 infection in COVID-19: A Retrospective Observational Experience. *Clin Infect Dis.* 2020  
215 Jul 1.

216 16. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory  
217 pathogens among COVID-2019 cases. *Virus Res.* 2020 Aug;285:198005.  
218  
219



220  
 221  
 222  
 223  
 224  
 225  
 226  
 227

Figure 1: Geographical distribution of the samples analyzed in this study. Distribution of the thirteen-health care center from where the samples were obtained. The figure shows the number of samples by health care center (black number below white circle). Red flag shows health cares center with SARS-CoV-2 positive cases, green flag shows health cares with SARS-CoV-2 negative cases, the human shape indicate population by location (A, B and C).

228 **Table 1.- Co-circulation and co-infection of seasonal respiratory viruses together with**  
 229 **SARS-CoV-2 in the Northern area of Santiago, Chile.**  
 230

Location	Health care center*	SARS-CoV-2	IAV	IBV	RSV	HRV	SARS-CoV-2/ IAV	SARS-CoV-2/ HRV
A	1	82/140 (58.6%)	2/140	0	0	2/140	0	1/140
A	2	43/89 (49.4%)	0	0	0	1/89	0	0
A	3	28/76 (38.4%)	0	0	0	0	0	0
A	4	57/117 (47.9%)	2/117	0	0	0	2/117	0
A	5	9/13 (69.2%)	0	0	0	0	0	0
B	6	87/134 (64.9%)	1/134	0	0	0	0	0
B	7	12/22 (54.56%)	0	0	0	0	0	0
B	8	48/82 (58.5%)	0	0	0	1/82	0	0
B	9	0/28	1/28	0	0	0	0	0
B	10	0/40	1/40	0	0	0	0	0
C	11	9/14 (64.3%)	0	0	0	0	0	0
C	12	7/23 (30.4%)	0	0	0	1/23	0	1/23
C	13	18/25 (72%)	0	0	0	1/40	0	0

231


232 **\* This study includes a total cohort of 800 individuals**

233

234

235

236



237

238

239 Figure 2.- Number distribution of COVID-19 cases according to age group and sex. from  
 240 April 1<sup>st</sup> to July 31<sup>st</sup> (2020) at Santiago of Chile. 400 patients are considered positive for  
 241 SARS-CoV-2; however, three patients did not provide any information about age and  
 242 gender. In red is shows female gender and in blue is shows male gender. The numbers  
 243 in the columns indicate SARS-CoV-2 positive cases by month.  
 244

245 **Materials and methods**

246 **Sample selection**

247

248 All samples in this study were obtained with nasopharyngeal swabs come from  
249 suspected Chilean population infected with SARS-CoV-2 in the north of Santiago de Chile  
250 from different health centers (figure 1). The samples were collected in 2 mL of RNA-  
251 shield media (GenoSUR) and store at room temperature until its analysis for SARS-CoV-  
252 2 detection.

253 **RNA extraction and Identification of respiratory viruses by RT-qPCR**

254 The RNA extraction was made using the Total RNA Purification Kit (Norgen Biotek CORP);  
255 following the manufacturing procedure, the RNA was a store at -80°C, which was used  
256 to perform RT-qPCR.

257 All samples were analyzed using a specific primer (Supplementary table 1) for SARS-CoV-  
258 2, IAV, IBV, RSV, and HRV. All sequences have been validated, and their use is a typical  
259 procedure to detect respiratory viruses from the World Health Organization (WHO). The  
260 viral genome detection was made using LightCycler® Multiplex RNA Virus Master  
261 (Roche) following the manufacturing procedure. The amplification and analysis plot was  
262 made in a QuantStudio3 Real Time PCR System 96 wells (Thermo Fisher Scientific). The  
263 HRV and IBV detection was performed by RT-PCR final point using specific primers, the  
264 retrotranscription step was made using SuperScript IV Reverse Transcriptase (Thermo  
265 Fisher Scientific) and PCR was using GoTaq® DNA polymerase (Promega), the genome  
266 of HRV was visualized in agarose – Seakem LE Agarose (LONZA) at 2% applying a voltage  
267 of 80 Volts for 30 minutes.

268

269  
270  
271  
272  
273  
274  
275  
276

**Supplementary Table 1.- Primers Sequence for SARS-CoV-2, IAV, IBV, RSV and HRV**

<b>Virus</b>	<b>Forward</b>	<b>Reverse</b>
SARS-CoV-2	5' ATGAGCTTAGTCCTGTTG 3'	5' CTCCTTTGTTGTGTTGT 3'
IAV,	5' GACCRATCCTGTCACCTCTGA C 3'	5' AGGGCATTYTGGACAAAKCGTCTA 3'
IBV,	5' GGAGCAACCAATGCCAC 3'	5' GTKTAGGCGGTCTTGACCAG-3'
RSV	5' AACAGATGTAAGCAGCTCCGTTATC 3'	5'- CGATTTTATTGGATGCTGTACATTT 3'
aHRV	5' CAAGCACTTCTGTTTCCC 3'	5' CACGGACACCCAAAGTAGT 3'

277  
278  
279  
280  
281  
282  
283  
  
284  
  
285  
286  
287